Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin

被引:87
作者
Chase, HP [1 ]
Dixon, B [1 ]
Pearson, J [1 ]
Fiallo-Scharer, R [1 ]
Walravens, P [1 ]
Klingensmith, G [1 ]
Rewers, M [1 ]
Garg, SK [1 ]
机构
[1] Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Dept Pediat, Denver, CO 80262 USA
关键词
D O I
10.1067/S0022-3476(03)00415-3
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective The purpose of this study was to evaluate the use of a new long-acting basal insulin, insulin glargine (IG), in children with type 1 diabetes. Study design Data from 114 subjects, age 2 to 18 years (mean, 12.2 years; 54 boys, 60, girls), were collected for 9 months before and 9 months after IG treatment. During IG therapy, all subjects received morning neutral protamine Hagedorn insulin (given with insulin lispro; Humalog) to provide daytime insulin coverage. The numbers of nonsevere and severe hypoglycemic events, hemoglobin Ale values body weight, and daily insulin dose were recorded at each clinic visit. Results The mean (+/-1 SEM) frequency of nonsevere hypoglycemie events per week decreased from 2.0 +/- 0.1 to 1.3 +/- 0.1 (P < .001). Severe hypoglycemic episodes were reduced from a total of 22 in the 9 months before IG to nine in the 9 months after IG. Severe nocturnal events were similarly reduced from 14 to four episodes. The mean (+/-1 SEM,) hemoglobin Ale levels were 9.6 +/- 0.1% (baseline), 9.4 +/- 0.16% at 3 months (P = .18),9.3 +/- 0.1% at 6 months (P = .03), and 9.3 +/- 0.1% at 9 months (P = .01). Conclusion insulin glargine therapy can reduce hypoglycemic episodes in children and adolescents with suboptimal glucose control without jeopardizing glycemic control.
引用
收藏
页码:737 / 740
页数:4
相关论文
共 15 条
[1]  
[Anonymous], 1996, DIABETES, V45, P1289
[2]   SEVERE HYPOGLYCEMIA IN IDDM CHILDREN [J].
BERGADA, I ;
SUISSA, S ;
DUFRESNE, J ;
SCHIFFRIN, A .
DIABETES CARE, 1989, 12 (04) :239-244
[3]   The impact of the Diabetes Control and Complications Trial and Humalog insulin or glycohemoglobin levels and severe hypoglycemia in type 1 diabetes [J].
Chase, HP ;
Lockspeiser, T ;
Peery, B ;
Shepherd, M ;
MacKenzie, T ;
Anderson, J ;
Garg, SK .
DIABETES CARE, 2001, 24 (03) :430-434
[4]  
Cryer PE, 1999, DIABETES-METAB RES, V15, P42, DOI 10.1002/(SICI)1520-7560(199901/02)15:1<42::AID-DMRR1>3.0.CO
[5]  
2-B
[6]  
DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z
[8]   Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo [J].
Heinemann, L ;
Linkeschova, R ;
Rave, K ;
Hompesch, B ;
Sedlak, M ;
Heise, T .
DIABETES CARE, 2000, 23 (05) :644-649
[9]   Intensive treatment of type 1 diabetes [J].
Hirsch, IB .
MEDICAL CLINICS OF NORTH AMERICA, 1998, 82 (04) :689-+
[10]   Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro [J].
Lepore, M ;
Pampanelli, S ;
Fanelli, C ;
Porcellati, F ;
Bartocci, L ;
Di Vincenzo, A ;
Cordoni, C ;
Costa, E ;
Brunetti, P ;
Bolli, GB .
DIABETES, 2000, 49 (12) :2142-2148